Chemistry:Dirozalkib

From HandWiki

Dirozalkib is a drug that was developed by Xuanzhu Biopharmaceutical for the treatment of non-small cell lung cancer. It is an anaplastic lymphoma kinase inhibitor.[1] [2][3][4]

It was approved for use in China in August of 2025.[5]

References

  1. ↑ "Dirozalkib". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800065417. 
  2. ↑ "Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer". European Journal of Cancer (Oxford) 235. February 2026. doi:10.1016/j.ejca.2026.116221. PMID 41539180. 
  3. ↑ "Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)". Cancer Chemotherapy and Pharmacology 95 (1): 122. December 2025. doi:10.1007/s00280-025-04837-x. PMID 41348226. 
  4. ↑ "A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer". Anticancer Research 46 (7): 3609–3618. July 2026. doi:10.21873/anticanres.18227. PMID 42373241. 
  5. ↑ S&P Capital IQ (22 August 2025). "The Innovative Drug Dirozalkib Tablets Independently Developed by Xuanzhu Biopharm Obtained Drug Registration Approval from NMPA". MarketScreener. https://www.marketscreener.com/news/the-innovative-drug-dirozalkib-tablets-independently-developed-by-xuanzhu-biopharm-obtained-drug-reg-ce7d5aded181ff26. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Dirozalkib&oldid=4583249"